Document is current
Any future updates will be listed below
-
Authors
Zhou, Xiaoyu
Zhao, Cheng
Xu, Haiyan
Xu, Yixiang https://orcid.org/0000-0003-4128-8832
Zhan, Li
Wang, Pei
He, Jingyi
Lu, Taotao
Gu, Yueling
Yang, Yan
Xu, Chanjuan https://orcid.org/0000-0002-5640-1896
Chen, Yiyang
Liu, Yuxuan
Zeng, Yue
Tian, Fuyun
Chen, Qian
Xie, Xin https://orcid.org/0000-0003-2314-4800
Liu, Jianfeng https://orcid.org/0000-0002-0284-8377
Hu, Hailan
Li, Jian https://orcid.org/0000-0002-7521-8798
Zheng, Yueming https://orcid.org/0000-0003-0677-0316
Guo, Jiangtao https://orcid.org/0000-0002-8850-286X
Gao, Zhaobing https://orcid.org/0000-0001-8931-5508
-
Funding
Funding for this research was provided by:
China National Funds for Distinguished Young Scientists (81825021)
National Natural Science Foundation of China (92169202, 2021ZD0200900)
Science and Technology Commission of Shanghai Municipality (2018SHZDZX05)
Youth Innovation Promotion Association of the Chinese Academy of Sciences (2020284)
Lingang Laboratory
MOE Frontier Science Center for Brain Science & Brain-Machine Integration, Zhejiang University
- License Information
-
More Information
Article History
Received: 6 February 2023
Accepted: 15 January 2024
First Online: 14 February 2024
Competing interests
: H.H. and Y.Y. are named on a patent for use of potassium channel inhibitors for treating depression (US20200149051A1). Z.G., X.Z., Y. Zheng, H.X., P.W., L.Z. and Y.G. are inventors on a patent pending for the use of Lys05 to treat depression or conditions related to Kir4.1 inhibition. All other authors declare no competing interests.
